Results 61 to 70 of about 27,256 (249)

Sitagliptin ameliorates busulfan-induced pulmonary and testicular injury in rats through antioxidant, anti-inflammatory, antifibrotic, and antiapoptotic effects

Scientific Reports, 2023
Busulfan (BUS) is an anticancer agent with serious adverse effects on various body organs, including the lung and testis. Sitagliptin was proven to have antioxidant, anti-inflammatory, antifibrotic, and antiapoptotic effects.
Eman A. Ali, Sara G. Tayel, Mona A. Abbas   +2 more
doaj   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Sitagliptin Is More Effective Than Gliclazide in Preventing  Pro-Fibrotic and Pro-Inflammatory Changes in a Rodent Model of Diet-Induced Non-Alcoholic Fatty Liver Disease

Molecules, 2022
A diet-induced non-alcoholic fatty liver disease (NAFLD) model causing obesity in rodents was used to examine whether sitagliptin and gliclazide therapies have similar protective effects on pathological liver change.
Jing Ren, Xiaoyu Wang, Christine Yee, Mark D. Gorrell, Susan V. McLennan, Stephen M. Twigg   +5 more
doaj   +1 more source

Circadian Immunity and Vascular Inflammation in Cardiovascular Disease Chronotherapy Windows: Time for a Re‐Assessment

Med Research, EarlyView.
ABSTRACT Circadian rhythms orchestrate cardiovascular physiology by regulating immune and inflammatory pathways. Disruption of these rhythms profoundly alters vascular homeostasis, thereby promoting the onset and progression of cardiovascular diseases (CVD).
Tian Zhang, Ge Zhang, Tian‐Ding Liu, Tianshu Gu, Fengyi Yu, Pengyuan Xu, Wunan Mi, Xuanjiang Zhao, Qian Guo, Honglin Zheng, Taiqi Zhao, Qiang Li, Di Lu, Mingxuan Duan, Chaoyang Yu, Ruhao Wu, Shiqian Zhang, Haonan Zhang, Zeyu Wang, Youyang Zheng, Yan Xiao, Zenglei Zhang, Ge Zhang   +22 more
wiley   +1 more source

Effect of concomitant administration of L-glutamine and cycloart-23-ene-3β, 25-diol (B2) with sitagliptin in GLP-1 (7-36) amide secretion, biochemical and oxidative stress in streptozotocin - nicotinamide induced diabetic Sprague Dawley rats. [PDF]

PLoS ONE, 2013
Previously we have reported that, cycloart-23-ene-3β, 25-diol (called as B2) and L-glutamine stimulated glucagon like peptide-1 (GLP-1) (7-36) amide secretion diabetic rats.
Sachin L Badole, Swapnil M Chaudhari, Pranita P Bagul, Sagar P Mahamuni, Rekha D Khose, Anuja C Joshi, Chandrashekhar G Raut, Anand A Zanwar   +7 more
doaj   +1 more source

Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study [PDF]

, 2018
Introduction: DPP-4 inhibitors (DPP4i) and sulfonylureas are popular second-line therapies for type 2 diabetes (T2D), but there is a paucity of real-world studies comparing their effectiveness in routine clinical practice. Methods: This was a multicenter
Avogaro Angelo, Baldi, Ileana, Bossi, Antonio Carlo, Bottigliengo, Daniele, Cavalot, Franco, D'Angelo, Federica, DARWIN-T2D Network, Fadini, Gian Paolo, Morano S., Raffaella Buzzetti, Zatti, Giancarlo   +10 more
core   +1 more source

Glucagon‐like peptide‐1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions

British Journal of Pharmacology, EarlyView.
Abstract Gastric inhibitory polypeptide (GIP)/Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are increasingly prescribed for the management of obesity and type 2 diabetes, yet research pertinent to their effects on muscle health is limited. Considering the central role of muscle strength as a sarcopenia component, this article summarizes emerging ...
Konstantinos Prokopidis
wiley   +1 more source

The Biological Impacts of Sitagliptin on the Pancreas of a Rat Model of Type 2 Diabetes Mellitus: Drug Interactions with Metformin

Biology, 2019
Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is a beneficial class of antidiabetic drugs. However, a major debate about the risk of developing pancreatitis is still existing.
Lamiaa M. Shawky, Ahmed A. Morsi, Eman El Bana, Safaa Masoud Hanafy   +3 more
doaj   +1 more source

Injection‐site and dermatologic reactions associated with glucagon‐like peptide‐1 receptor agonists: Insights from meta‐analysis of randomised controlled trials and real‐world evidence

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely used for type 2 diabetes mellitus and obesity, with once‐weekly dosing that supports adherence. However, injection‐site reactions (ISRs) and dermatologic events have been recognised, ranging from mild local events to rare systemic hypersensitivity reactions that may cause ...
Shifa Taj, Mohammed Zuber, Muhammed Rashid, Manik Chhabra, Krishna Undela, Smita Rawal, Lorenzo Villa Zapata   +6 more
wiley   +1 more source

Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures

Neurobiology of Disease, 2012
Increasing evidence supports an association between Alzheimer's disease (AD) and diabetes. In this context, anti-diabetic agents such as rosiglitazone and glucagon-like peptide (GLP)-1 have been reported to reduce pathologies associated with AD ...
Dong-Hou Kim, Jae-Wan Huh, Mi Jang, Jung-Hyun Suh, Tae-Wan Kim, Jeong-Su Park, Seung-Yong Yoon   +6 more
doaj   +1 more source